Could a rheumatoid arthritis drug ease Sjogren's symptoms?

NCT ID NCT05016297

Completed Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether baricitinib, a drug already used for rheumatoid arthritis, can help people with active Sjogren's syndrome. 87 participants were randomly assigned to receive either hydroxychloroquine alone or baricitinib plus hydroxychloroquine for 24 weeks. The goal was to see if baricitinib improves disease activity and symptoms like dryness and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baricitinib
What this could lead to: If it works, this could point toward a new treatment option for Sjogren's syndrome, a chronic autoimmune disease causing dry eyes and mouth.
What could go wrong: This is a small, early-phase trial (phase 2) with only 87 participants. Results may not apply to all patients, and baricitinib carries risks like infections and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJOGREN'S SYNDROME

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.